Art. -Nr.: HY-W013331

Deoxyartemisinin

(Synonyms: 2-Deoxyartemisinin)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Deoxyartemisinin (2-Deoxyartemisinin) is an orally active anti-inflammatory and analgesic agent. Deoxyartemisinin selectively reduces the level of the pro-inflammatory cytokine TNF-α. Deoxyartemisinin alleviates neuropathic pain, inflammatory pain, and croton oil-induced ear edema.\nDeoxyartemisinin exerts an analgesic effect against thermal stimulation. Deoxyartemisinin has anti-ulcer activity. Deoxyartemisinin can be used in research related to inflammatory diseases, pain, and gastric ulcers.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.76%
CAS. Nr.: 72826-63-2
Formel: C₁₅H₂₂O₄
Molecular Weight:266.33

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Deoxyartemisinin Chemical Structure

CAS. Nr.: 72826-63-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- Parmacokinetics
- In Vivo
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Alle TNF Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	>50 μM Compound: DART	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay	[PMID: 38287228]
HUVEC	IC₅₀	>50 μM Compound: 12	Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay	[PMID: 14552753]

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_last	AUC_inf	MRT_last	C₀	V_z	CL
Rat^[2]	5 mg/kg	i.v.	1.45 h	/	/	219 ng·h/mL	222 ng·h/mL	0.671 h	1069 ng/mL	48.3 L/kg	385 mL/min/kg
Rat^[2]	100 mg/kg	p.o.	1.12 h	0.389 h	62.4 ng/mL	67.3 ng·h/mL	71.0 ng·h/mL	1.21 h	/	/	/

In Vivo

Deoxyartemisinin (10-300 mg/kg; i.p.; single administration) reduces formaldehyde-induced neuropathic pain by 56.55% and inflammatory pain by 45.43% in male Swiss mice, exerts dose-dependent analgesic effects in the tail-flick test, and impairs spontaneous activity and motor coordination in male Swiss mice at the dose of 300 mg/kg^[1].
Deoxyartemisinin (100 mg/kg; i.p.; single administration) reduces croton oil-induced ear swelling by 33.64% and selectively decreases TNF-α levels by 37.37% in male Swiss mice^[1].
Deoxyartemisinin (50-200 mg/kg; p.o.; single administration) dose-dependently reduces the gastric ulcer injury index in ethanol-induced male Wistar rats, with an ED₅₀ of 87.5 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss mice (male, 25-35 g)^[1]
Dosage:

10 mg/kg; 30 mg/kg; 100 mg/kg
Administration:

i.p.; single dose
Result:

Reduced neurogenic pain by 0% and inflammatory pain by 1.69% (10 mg/kg).
Reduced neurogenic pain by 9.26% and inflammatory pain by 0% (30 mg/kg).
Reduced neurogenic pain by 56.55% and inflammatory pain by 45.43% (100 mg/kg).
Exerted a dose-dependent antinociceptive effect in the tail flick test

Animal Model:

Swiss mice (male, 25-35 g)^[1]
Dosage:

100 mg/kg
Administration:

i.p.; single dose
Result:

Reduced croton oil-induced ear edema by 33.64% compared to vehicle group.
Selectively reduced tumor necrosis factor alpha (TNF-α) levels by 37.37%, with no significant reduction in interleukin-1beta (IL-1β) or interleukin-6 (IL-6) levels.

Animal Model:

Wistar rats (male, 200-300 g)^[1]
Dosage:

50 mg/kg; 100 mg/kg; 200 mg/kg
Administration:

p.o.; single dose
Result:

Reduced ulcerative lesion index by 49.7% (50 mg/kg).
Reduced ulcerative lesion index by 74% (100 mg/kg).
Reduced ulcerative lesion index by 76.5% (200 mg/kg).
Had an effective dose 50 (ED50) of 87.5 mg/kg.

Chemical Information

CAS. Nr. 72826-63-2
Appearance Solid
Molecular Weight 266.33
Formel C₁₅H₂₂O₄
Color White to off-white
SMILES

C[C@@H]1[C@@](CC[C@H]2C)([H])[C@@]([C@@]2([H])CC3)(O4)[C@@](OC1=O)([H])O[C@@]34C
Synonyms

2-Deoxyartemisinin
Initial Source

Nocardia cwallina
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Structure

Antimalarial drug artemisinin stabilizes PfRACK1 binding to the ribosome. [Abstract]

2025 May 27:S0969-2126(25)00186-8. PMID: 40480224

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Favero FF, et al. Artemisinin and deoxyartemisinin isolated from Artemisia annua L. promote distinct antinociceptive and anti-inflammatory effects in an animal model. Biomed Pharmacother. 2024;178:117299. [Content Brief]

[2]. Fu C, et al. Oral Bioavailability Comparison of Artemisinin, Deoxyartemisinin, and 10-Deoxoartemisinin Based on Computer Simulations and Pharmacokinetics in Rats. ACS Omega. 2020;6(1):889-899. Published 2020 Dec 28. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Deoxyartemisinin

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Deoxyartemisinin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Differentiation Inducing Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Deoxyartemisinin

Alle TNF Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Deoxyartemisinin Related Classifications

Art. -Nr.: HY-W013331